X-vir 0.5 Mg Tablets

Description

What Is X-Vir 0.5mg Tablet?

X-Vir 0.5mg Tablet is a potent oral prescription antiviral medicine manufactured by Natco Pharma Ltd. Each film-coated tablet contains Entecavir 0.5 mg.

X-Vir belongs to the pharmacological class of nucleoside reverse transcriptase inhibitors (NRTIs). It is prescribed under specialist medical supervision (by hepatologists, gastroenterologists, or infectious disease physicians) as a first-line treatment for Chronic Hepatitis B Virus (HBV) infection in adult and adolescent patients with active viral replication and liver inflammation.

The 0.5mg strength is the standard, globally recognized starting dose for patients who are treatment-naive (those who have never previously taken nucleoside analogue antiviral medications such as lamivudine).

Quick Product Fact Sheet

• Brand Name: X-Vir 0.5mg Tablet
• Active Ingredient: Entecavir (0.5 mg)
• Manufacturer: Natco Pharma Ltd.
• Therapeutic Class: Antiviral agent
• Pharmacological Class: Guanosine nucleoside analogue / NRTI
• Dosage Form: Film-coated oral tablet
• Packaging: Bottle or strip of 30 tablets
• Standard Adult Dose: One 0.5mg tablet once daily on an empty stomach
• Primary Indication: Chronic Hepatitis B (HBV) in treatment-naive adult and pediatric patients

How Does X-Vir 0.5mg Work?

The Hepatitis B virus replicates inside human liver cells (hepatocytes) using its own specialized viral enzyme known as HBV DNA polymerase.

Entecavir is a synthetic guanosine nucleoside analogue designed to block this enzyme. Once absorbed, it is converted by intracellular kinases into its active biological form: entecavir triphosphate. Active entecavir triphosphate inhibits all three primary steps of the HBV DNA polymerase enzyme:

• Base Priming: Prevents the initial linkage required to start building new viral DNA strands.
• Reverse Transcription: Blocks the synthesis of the negative-strand DNA from pregenomic RNA.
• Positive-Strand DNA Synthesis: Halts the formation of the complementary second DNA strand.

By inhibiting all three sequential steps, X-Vir stops the virus from replicating, lowers the amount of virus in the blood to undetectable levels, reduces liver inflammation, and lowers the long-term risk of developing cirrhosis and liver cancer (hepatocellular carcinoma).

Approved Clinical Indications

X-Vir 0.5mg Tablet is indicated for adult and pediatric patients (aged 2 years and older, weighing at least 10 kg with appropriate dosing formulations) in the following settings:

• Compensated Liver Disease in Treatment-Naive Adults: Indicated for adults with chronic hepatitis B who have evidence of active viral replication, persistently elevated liver enzymes (ALT or AST), or histologically active liver disease who have not received prior nucleoside analogue therapy.
• Compensated Liver Disease in Pediatric Patients: Indicated for nucleoside-naive pediatric patients aged 2 years and older with active viral replication and abnormal liver enzymes or active inflammation.
• HIV/HBV Co-Infection (Only with Full cART): Can be used to treat Hepatitis B in patients co-infected with HIV, provided they are simultaneously receiving an effective, complete combination antiretroviral regimen for HIV.

Important Note: X-Vir is not a permanent cure for Hepatitis B and does not prevent the transmission of HBV to others through sexual contact, sharing needles, or exposure to blood.

Standard Dosage and Administration Guidelines

X-Vir 0.5mg must be taken strictly as prescribed by your doctor.

• Standard Adult Dose (Treatment-Naive): One 0.5mg tablet taken orally once daily.
• The Strict Empty-Stomach Requirement: Food significantly slows and reduces the absorption of entecavir into the bloodstream. You must take X-Vir on an empty stomach:
  • Take the tablet at least 2 hours before a meal, OR
  • Wait at least 2 hours after your last meal or snack before taking your dose.
• How to Take: Swallow the tablet whole with a full glass of plain water. Do not chew, crush, break, or dissolve the tablet.
• Daily Consistency: Take your tablet at the exact same time every day to maintain steady medicine levels in your bloodstream.

Dose Adjustments for Reduced Kidney Function

Entecavir is cleared primarily through the kidneys. Patients with impaired kidney filtration require adjusted dosing intervals:

• 50 mL/min or higher: One 0.5mg tablet every 24 hours (standard daily dose)
• 30 to 49 mL/min: One 0.5mg tablet every 48 hours
• 10 to 29 mL/min: One 0.5mg tablet every 72 hours
• Hemodialysis Patients: One 0.5mg tablet every 7 days (taken immediately after dialysis)

Missed Dose Instructions

• If you miss a dose by less than 12 hours, take it on an empty stomach as soon as you remember.
• If it is within 12 hours of your next scheduled dose, skip the missed dose and resume your regular timing the next day.
• Never take two tablets at once to make up for a missed dose.

Potential Side Effects & Clinical Management

X-Vir 0.5mg is generally well tolerated, with most side effects being mild and temporary.

Common Side Effects

• Nervous System: Headache, fatigue, dizziness, or insomnia (trouble sleeping).
• Digestive: Mild nausea, diarrhea, indigestion, or upper abdominal discomfort.
• Liver Enzymes: Temporary, mild elevations in alanine aminotransferase (ALT) levels as the immune system clears infected liver cells.

Serious Warnings (Seek Immediate Medical Attention)

• Severe Hepatitis B Flare-ups (Black Box Warning): Stopping X-Vir abruptly can trigger sudden, severe, and potentially fatal reactivation of the Hepatitis B virus. Never stop taking this medicine without your doctor’s supervision.
• Lactic Acidosis and Severe Fatty Liver (Hepatomegaly with Steatosis): A rare but serious metabolic complication associated with nucleoside analogues. Seek urgent medical care for deep muscle aches, rapid or difficult breathing, severe stomach pain, cold hands and feet, or sudden extreme fatigue.
• Undiagnosed HIV Resistance Risk: If an individual has an untreated or undiagnosed HIV infection, taking entecavir alone can cause the HIV virus to mutate and develop resistance to other essential HIV medicines.

Precautions & Routine Safety Monitoring

• HBV DNA Viral Load: Baseline, then every 3 to 6 months to track how effectively the virus is being suppressed.
• Liver Function Tests (ALT, AST, Bilirubin): Baseline, then every 1 to 3 months to monitor for liver enzyme normalization or sudden inflammatory spikes.
• Kidney Function (eGFR / Serum Creatinine): Baseline and periodic to determine whether dosing intervals need to be adjusted.
• HIV-1 Antibody Screening: Mandatory prior to starting therapy to confirm absence of HIV to avoid creating drug-resistant HIV strains.
• Liver Ultrasound / AFP (Alpha-Fetoprotein): Every 6 months to screen for early signs of cirrhosis progression or liver tumors.

Drug Interactions & Substance Warnings

• Kidney-Clearing Medicines: Because entecavir is eliminated through kidney tubules, taking it alongside drugs that reduce kidney function or compete for renal tubular secretion (such as aminoglycosides, cyclosporine, or tacrolimus) can increase entecavir blood levels.
• Alcohol: Strictly avoid or minimize alcohol consumption. Alcohol increases liver inflammation and accelerates liver scarring, working directly against the benefits of your hepatitis treatment.
• Other Hepatitis B Medicines: Do not combine X-Vir 0.5mg with other entecavir formulations or brands unless instructed by a specialist. Inform your doctor if you have ever taken lamivudine, adefovir, or tenofovir.

Special Population Guidance

• Pregnancy: Given only if the potential benefit clearly outweighs the potential risk to the fetus. Consult your doctor if planning pregnancy.
• Breastfeeding: It is unknown if entecavir passes into human breast milk. Breastfeeding is generally not recommended while on treatment unless approved by a physician.
• Kidney Disease: Dose intervals must be adjusted if creatinine clearance is below 50 mL/min.
• Pediatric Use: Approved for pediatric patients 2 years of age and older. Children must be able to swallow tablets or use oral solution formulations.

Storage and Handling Protocols

• Store tablets at room temperature between 20°C and 25°C (68°F to 77°F).
• Keep tablets in their original packaging, tightly closed, in a dry place protected from direct heat, moisture, and light.
• Keep strictly out of reach of children and pets.

Frequently Asked Questions (FAQs)

Q1: What is the difference between X-Vir 0.5mg and X-Vir 1mg?
The 0.5mg strength is standard for patients who have never taken antiviral medications before (treatment-naive). The 1mg strength is reserved for patients whose virus has developed resistance to older medications like lamivudine, or for patients with advanced decompensated liver disease.

Q2: Why must I take X-Vir 0.5mg on an empty stomach?
Food significantly reduces the amount of entecavir your body absorbs. To ensure that the full dose enters your bloodstream to suppress the virus, you must take it at least 2 hours before or 2 hours after eating.

Q3: Can I stop taking X-Vir once my viral load becomes undetectable?
No. An undetectable viral load means the medication is working successfully to keep the virus suppressed. Stopping treatment can cause the virus to rebound rapidly, leading to severe liver flares and potentially life-threatening liver failure.

Q4: Does X-Vir cure Hepatitis B permanently?
X-Vir does not remove dormant viral genetic material (cccDNA) from the liver, so it is not a permanent cure. However, long-term daily use suppresses the virus, allows the liver to heal, and significantly lowers the lifetime risk of cirrhosis and liver cancer.

Medical Disclaimer: This clinical guide is strictly for educational and informational purposes and should not replace professional medical advice, diagnosis, or treatment. Always consult a qualified hepatologist, gastroenterologist, or healthcare provider before starting, stopping, or modifying any antiviral therapy.

References

• U.S. Food and Drug Administration (FDA): Baraclude (entecavir) Full Prescribing Information. View Source
• National Center for Biotechnology Information (NCBI): StatPearls Review: Entecavir Pharmacology, Indications, and Clinical Use. View Source
• European Association for the Study of the Liver (EASL): Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. View Source
• MedlinePlus (U.S. National Library of Medicine): Entecavir Monograph & Patient Instructions. View Source